Veradermics, Incorporated (MANE)

NYSE: MANE · Real-Time Price · USD

102.82

-2.50 (-2.37%)

Aug 21, 2026, 4:00 PM EDT - Market closed

Veradermics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	26.95	10.28	3.5	2.35
Research & Development	75.82	62.07	23.28	14.97
Operating Expenses	102.77	72.35	26.78	17.32
Operating Income	-102.77	-72.35	-26.78	-17.32
Interest Expense	-	-	-0.59	-0.04
Interest & Investment Income	8.3	1.56	0.48	0.87
Other Non Operating Income (Expenses)	1.79	0.79	0.39	-
Pretax Income	-92.68	-70	-26.49	-16.49
Net Income	-92.68	-70	-26.49	-16.49
Preferred Dividends & Other Adjustments	11.61	13.38	0.82	-
Net Income to Common	-104.29	-83.37	-27.3	-16.49
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	16	1	1	1
Shares Outstanding (Diluted)	16	1	1	1
Shares Change	-	1.09%	-	-
EPS (Basic)	-6.44	-111.91	-37.05	-22.38
EPS (Diluted)	-6.44	-111.91	-37.05	-22.38
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-78.33	-71.63	-23.69	-13.51
Free Cash Flow Per Share	-4.84	-96.14	-32.14	-18.33
EBIT	-102.77	-72.35	-26.78	-17.32

SEC Filings: 10-K · 10-Q